实验室服务提供商Labcorp周五宣布与美国肿瘤临床试验联盟达成合作，共同推进一项针对新确诊结直肠癌患者的全国性、多中心临床研究。该试验旨在评估提高高危家庭成员胚系基因检测覆盖率的新方法，以及多基因联合检测对新确诊患者治疗的临床影响。 据统计，约10%的结直肠癌病例与遗传性基因变异有关。对携带癌症相关变异基因的个体家庭成员进行检测即级联检测是公认的癌症预防方法，尤其对于最常见的遗传性结直肠癌综合征 ...

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer The Labcorp Plasma Detect integrated whole-genome sequencing sample-to-report ...

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of ...

The trial will assess if direct outreach by healthcare providers increases cascade genetic testing among first-degree relatives.